SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Estée Lauder Sues Jo Malone Over Trademark Dispute Involving Zara 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
xAI Faces Lawsuit Over Grok AI-Generated Sexual Content Involving Minors 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
FEMA Reinstates $1 Billion Disaster Prevention Grant Program After Court Order 
Jerome Powell May Stay on Fed Board Amid Criminal Investigation, Court Documents Reveal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Federal Judge Blocks Pentagon's Restrictive Press Access Policy 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
